文献速递肝病

miR-145a-5p下调通过上调Nr4a2促进脂肪变性向NASH进展

Downregulation of microRNA-145a-5p promotes steatosis-to-NASH progression through upregulation of Nr4a2.
PubMed 文献 · J Hepatol · 2023-07-16

本研究探讨微小RNA-145a-5p在单纯脂肪变性向非酒精性脂肪性肝炎(NASH)进展中的作用及机制。小鼠功能缺失与功能获得实验显示,抑制miR-145a-5p加重脂质蓄积并激活炎症、肝损伤和纤维化,而恢复其表达可减轻饮食诱导的NASH;机制上miR-145a-5p下调核受体Nr4a2,NASH患者肝内miR-145a-5p降低、Nr4a2升高。

要点

  • 肝内抑制miR-145a-5p加重脂肪变性小鼠的脂质蓄积、炎症、肝损伤和纤维化。
  • 恢复miR-145a-5p表达可显著减轻饮食诱导的NASH发病。
  • NASH患者肝内miR-145a-5p表达降低、Nr4a2表达升高。

核心结论

  • miR-145a-5p/Nr4a2调控轴参与脂肪变性向NASH进展,补充miR-145a-5p或药物抑制肝细胞Nr4a2可能为NASH治疗提供有前景的途径。

研究设计与样本

  • 研究采用体内功能缺失与功能获得实验探索miR-145a-5p和Nr4a2在NASH进展中的作用,并用RNA测序和生物信息学分析研究miR-145a-5p的靶点。
  • 在脂肪变性小鼠中抑制miR-145a-5p,并在饮食诱导NASH模型中观察其恢复效应。
  • 在NASH患者肝脏中检测miR-145a-5p与Nr4a2表达,并在原代人肝细胞中验证该调控轴。

主要发现

  • 脂肪变性小鼠肝内抑制miR-145a-5p加重脂质蓄积并激活肝脏炎症、肝损伤和纤维化。
  • 恢复miR-145a-5p表达显著减轻饮食诱导的NASH发病。
  • miR-145a-5p下调核受体Nr4a2,从而抑制NASH相关基因表达。
  • Nr4a2过表达促进脂肪变性向NASH进展,而肝特异性Nr4a2敲除小鼠免受饮食诱导的NASH。
  • NASH患者肝内miR-145a-5p表达降低、Nr4a2表达升高,且分别与肝脏病理特征显著负相关和正相关。

关键数值与推荐

  • 原文未报告具体数值、阈值或推荐等级。

临床怎么用

  • 作者认为,补充miR-145a-5p或药物抑制肝细胞Nr4a2可能为NASH治疗提供有前景的途径。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The molecular mechanisms underlying the progression of simple steatosis to non-alcoholic steatohepatitis (NASH) remain incompletely understood, though the potential role of epigenetic regulation by microRNA (miRNAs) is an area of increasing interest. In the present study, we aimed to investigate the role of miRNAs during steatosis-to-NASH progression, as well as underlying mechanisms. METHODS: miR-145a-5p was identified as an important checkpoint in steatosis-to-NASH progression. In vivo loss-of-function and gain-of-function studies were performed to explore the role of miR-145a-5p and Nr4a2 in NASH progression. RNA-sequencing and bioinformatic analysis were used to investigate the targets of miR-145a-5p. RESULTS: Suppression of miR-145a-5p in the liver aggravated lipid accumulation and activated hepatic inflammation, liver injury and fibrosis in steatotic mice, whereas its restoration markedly attenuated diet-induced NASH pathogenesis. Mechanistically, miR-145a-5p was able to downregulate the nuclear receptor Nr4a2 and thus inhibit the expression of NASH-associated genes. Similarly, Nr4a2 overexpression promoted steatosis-to-NASH progression while liver-specific Nr4a2 knockout mice were protected from diet-induced NASH. This role of the miR-145a-5p/Nr4a2 regulatory axis was also confirmed in primary human hepatocytes. Furthermore, the expression of miR-145a-5p was reduced and the expression of Nr4a2 was increased in the livers of patients with NASH, while their expression levels significantly negatively and positively correlated with features of liver pathology, respectively. CONCLUSIONS: Our findings highlight the role of the miR-145a-5p/Nr4a2 regulatory axis in steatosis-to-NASH progression, suggesting that either supplementation of miR-145a-5p or pharmacological inhibition of Nr4a2 in hepatocytes may provide a promising therapeutic approach for the treatment of NASH. IMPACT AND IMPLICATIONS: Non-alcoholic fatty liver disease (NAFLD) is a dynamic spectrum of chronic liver diseases ranging from simple steatosis to non-alcoholic steatohepatitis (NASH). Unfortunately, there are currently no approved drugs for NASH. Our current study identified miR-145a-5p as a novel regulator that inhibits steatosis-to-NASH progression. We found that miR-145a-5p was able to downregulate the nuclear receptor Nr4a2 to suppress the expression of NASH-associated genes. The differential expression of miR-145a-5p and Nr4a2 was further confirmed in patients with NASH, raising the possibility that supplementation of miR-145a-5p or suppression of Nr4a2 in hepatocytes might provide novel strategies for treating NASH.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Li B, Yang Z, Mao F, et al. Downregulation of microRNA-145a-5p promotes steatosis-to-NASH progression through upregulation of Nr4a2. J Hepatol. 2023. PMID: 37463623. doi:10.1016/j.jhep.2023.06.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。